I am a
Home I AM A Search Login

Papers of the Week

Papers: 9 Jul 2022 - 15 Jul 2022

Pharmacology/Drug Development

2022 Jul 09

Int J Pharm

Design, Characterization and In Vivo Performance of Solid Lipid Nanoparticles (SLNs)-Loaded Mucoadhesive Buccal Tablets for Efficient Delivery of Lornoxicam in Experimental Inflammation.


Zewail MB, Asaad GF, Swellam SM, Abd-Allah SM, K Hosny S, Sallah SK, E Eissa J, S Mohamed S, El-Dakroury WA
Int J Pharm. 2022 Jul 09:122006.
PMID: 35820515.


Lornoxicam (LRX) is a potent nonsteroidal anti-inflammatory drug (NSAID) used extensively to manage pain and inflammatory conditions. However, the drug possesses poor aqueous solubility (i.e., BCS class II) and a short half-life (3-4h). Mucoadhesive buccal tablets containing LRX -loaded solid lipid nanoparticles (SLNs) were developed to enhance the drug solubility and bioavailability and achieve a controlled release pattern for a better anti-inflammatory effect. Different LRX-loaded SLNs were prepared using the hot homogenization /ultra-sonication technique and evaluated using size analysis and entrapment efficiency (EE%). Optimized LRX -loaded SLNs formulation showed particle size of 216± 7.4 nm, zeta potential of -27.3±4.6 mV, and entrapment efficiency of 92.56± 2.3 %. Dried LRX-loaded SLNs alongside mucoadhesive polymers blend (PVP K30 /HPMC K15) were compressed to prepare the mucoadhesive buccal tablets. The tablets showed proper physicochemical properties, good mucoadhesive strength, long mucoadhesive time, suitable pH surface, good swelling capacity, and controlled drug release profile. Furthermore, Fourier transform-infrared (FTIR) spectroscopy, Powder X-Ray diffraction (PXRD), and Scanning electron microscopy (SEM) studies were carried out. The in vivo anti-inflammatory effect of pure LRX, market LRX and optimized mucoadhesive buccal tablet of LRX -loaded SLNs (T3) against carrageenan-induced models were evaluated. T3 showed a significant and early anti-inflammatory response after 1 and 2 h (63.62 – 77.84 % inhibition) as well as an extended effect after 4 h as compared to pure and market LRX. In parallel, T3 showed the best amelioration of PGE2, COX2, and TNF-α serum levels after 4 h of carrageenan injection.